January 2014

J Psychiatry Neurosci 2014;39(1)


Light up your life: Optogenetics for depression?
P.R. Albert

Review Paper

Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology
S. Comai, G. Gobbi

Research Papers

Abnormal interhemispheric connectivity in male psychopathic offenders
S.S. Hoppenbrouwers, D.R. De Jesus, Y. Sun, T. Stirpe, D. Hofman, J. McMaster, G. Hughes, Z.J. Daskalakis, D.J.L.G. Schutter

Association of a risk allele of ANK3 with cognitive performance and cortical thickness in patients with first-episode psychosis
C. Cassidy, L. Buchy, M. Bodnar, J. Dell’Elce, Z. Choudhry, F. Fathalli, S. Sengupta, R. Fox, A. Malla, M. Lepage, S. Iyer, R. Joober

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
D. Bakish, A. Bose, C. Gommoll, C. Chen, R. Nunez, W.M. Greenberg, M. Liebowitz, A. Khan

Effect of childhood maltreatment on brain structure in adult patients with major depressive disorder and healthy participants
A. Chaney, A. Carballedo, F. Amico, A. Fagan, N. Skokauskas, J. Meaney, T. Frodl

Cerebellar motor learning deficits in medicated and medication-free men with recent-onset schizophrenia
M. Coesmans, C.H. Röder, A.E. Smit, S.K.E. Koekkoek, C.I. De Zeeuw, M.A. Frens, J.N. van der Geest


Possible role of more positive social behaviour in the clinical effect of antidepressant drugs
S.N. Young, D.S. Moskowitz, M. aan het Rot


2013 Reviewers

Psychopharmacology for the Clinician

Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects
G. Remington, M. Hahn